Field Medical, Inc. Announces Oversubscribed Seed Round to Advance Next-Generation Cardiac Ablation Technology
Field Medical, Inc. has successfully closed its oversubscribed seed round, securing a total of $14 million in investments. The funding, led by private investors and supported by multiple strategic investors, will be used to develop and test the company’s proprietary FieldBending catheter ablation platform. This platform represents a significant advancement in the treatment of cardiac arrhythmias, addressing a major unmet need in the $3.6 billion cardiac catheter ablation market.
Advancing Cardiac Ablation Technology
Field Medical, Inc. is at the forefront of developing a second-generation pulse field ablation (PFA) system. This technology represents a major step forward in overcoming the limitations of first-generation PFA technologies and addresses the growing demand for more effective treatments for cardiac arrhythmias. The company’s core products, the FieldForce Catheter and the FieldForce Generator, utilize the proprietary FieldBending technology.
Revolutionizing the Cardiac Ablation Market
Field Medical, Inc. aims to revolutionize the cardiac ablation market by providing innovative tools that go beyond current indications. The company’s lean start-up environment allows for pioneering advancements in catheter ablation, with a focus on expanding the applications of PFA technology. By exploring new market opportunities and addressing unmet needs, Field Medical, Inc. is poised to redefine pulsed field catheter ablation.
Paving the Way for Future Growth
Field Medical, Inc. anticipates sharing preliminary clinical results in mid-2024, positioning the company for further growth. The team is committed to completing all necessary clinical pilot studies and securing regulatory approvals, including CE Mark and FDA approval, through pivotal trials. With a talented team leading the way, Field Medical, Inc. is on track to commercialize their next-generation cardiac ablation technology.
Field Medical, Inc. is dedicated to being the industry leader in pulsed field catheter ablation, providing physicians with the technology they need and patients with the treatments they deserve. The successful oversubscribed seed round demonstrates the strong interest from investors and strategic partners in Field Medical, Inc.’s innovative approach to cardiac ablation.
About Field Medical, Inc.
Field Medical, Inc. is a world leader in focal pulsed field catheter ablation technology, founded by Dr. Steven Mickelsen, a renowned cardiac electrophysiologist and expert in pulse field ablation. The company’s mission is to develop and commercialize next-generation cardiac ablation technologies that revolutionize the treatment of cardiac arrhythmias.
